Stopping Ipi/Nivo for irAEs Did Not Affect Advanced Melanoma Survival

Source: Cancer Therapy Advisor, July 2021

Patients with advanced melanoma who must discontinue induction treatment with nivolumab plus ipilimumab because of immune-related adverse events (irAEs) did not have adversely affected overall survival or time to treatment failure, according to the results of a study of non-trial participants published in Clinical Oncology.

The multicenter study included 95 patients with unresectable stage III to IV disease who received first-line combination immunotherapy.

READ THE ORIGINAL FULL ARTICLE